Announcements
- Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari – 30 juni 2023
- Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023
- New number of shares and votes in IBT
- Nytt antal aktier och röster i IBT
- IBT announces outcome of its rights issue
- IBT offentliggör utfall i företrädesemissionen
- Ytterligare Infant Bacterial Therapeutics produkt beviljas “orphan drug” status av FDA
- Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
- Futilitetsanalysen för IBTs Connection Study positiv
- The futility analysis for IBT’s Connection Study positive
More ▼
Key statistics
On Friday, Infant Bacterial Therapeutics AB (9IB:STU) closed at 8.52, -7.79% below its 52-week high of 9.24, set on Jan 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.54 |
---|---|
High | 8.66 |
Low | 8.50 |
Bid | 8.40 |
Offer | 8.88 |
Previous close | 8.60 |
Average volume | 150.00 |
---|---|
Shares outstanding | 13.02m |
Free float | 11.38m |
P/E (TTM) | -- |
Market cap | 1.30bn SEK |
EPS (TTM) | -9.96 SEK |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼